WuXi AppTec sues to get its name removed from U.S. blacklist
Pharmaceutical services provider WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) has sued the U.S. Defense Department, seeking to have its name removed from the department’s list of Chinese companies with military…
BRIEF: Shimai Pharma gets CSRC nod for Hong Kong IPO
Zhejiang Shimai Pharmaceutical Co. Ltd., a developer of T-cell engager (TCE) therapies, has been cleared by the China Securities Regulatory Commission (CSRC) for its overseas listing, marking an important step…
BRIEF: WuXi Biologics maintains full-year revenue guidance for up to 17% growth
Drug development services company WuXi Biologics (Cayman) Inc. (2269.HK) announced on Sunday that it had secured 69 new integrated projects as of April 30, with approximately two-thirds originating from clients…
BRIEF: So-Young revenue jumps on aesthetic center growth as loss widens
Medical aesthetics platform So-Young International Inc. (SY.US) reported on Friday that its first-quarter revenue rose 45.6% year-on-year to 433 million yuan ($64 million), mainly driven by growth in its self-operated aesthetic medical…
BRIEF: Heavily oversubscribed TenNor Therapeutics soars in trading debut
Shares of Biotechnology firm TenNor Therapeutics (Suzhou) Ltd. (6872.HK) nearly tripled in their Hong Kong debut on Friday, doubling when trading began and rising throughout the day to close at HK$211, up 179%.…
BRIEF: Legend Biotech’s revenue jumps on growing momentum for cancer treatment
Drug developer Legend Biotech Corp. (LEGN.US) on Tuesday reported its revenue rose 56% year-on-year to $305.1 million in the first quarter, as it reaped the benefit of strong sales for…
BRIEF: Zai Lab revenue falls on fading sales for its best-selling drug
Drug developer Zai Lab Ltd. (ZLB.US; 9688.HK) on Thursday reported its revenue fell 6% to $99.6 million in the first quarter from $106.5 million a year earlier, blaming a big…
